For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Busulfan 32 mg/m2 by vein test dose administrated either as an outpatient before Day -14 or as an inpatient on Day -9. Busulfan pharmacokinetics performed. Doses of days -7 to -4 subsequently adjusted to target an area under curve (AUC) of 4,000 microMol.min-1. In the event that PK adjusting was not possible a dose of busulfan of 130 mg/m2 administered.
Treatment Plan #1: 10 mg/m2 by vein on Days -7 to -4. Participants </= 2 years of age receive Fludarabine 1.3 mg/kg.
Treatment Plan # 2: 40 mg/m2 by vein on Days -6 to -3.
Treatment Plan # 3: 40 mg/m2 by vein on Days -5 to -2.
30 mg/m2 by vein on Days -7 to -4.
Drug: Rabbit ATG
Treatment Plan # 1 + Treatment Plan # 2: 1.25 mg by vein on Day -4 and 1.75 mg by vein on Day -3.
Treatment Plan # 3: 1.25 mg by vein on Day -3 and 1.75 mg by vein on Day -2.
Rabbit Antithymocyte Globulin
Rabbit Antilymphocyte Globulin
Radiation: Total Body Irradiation (TBI)
Treatment Plan #1: TBI 2 Gy in AM on Day -3.
Treatment Plan #2: TBI 2 Gy on Day -1.
Procedure: Cord Blood Infusions
Cord blood infusions on Day 0.
375 mg/m2 by vein on Day -9 for participants with CD20+ malignancies.
Other Name: Rituxan
50 mg/kg by vein on Day -6.
Procedure: Natural Killer Cell Infusion
NK Cell Infusion (C2C2 subgroup only) on Day +34.
140 mg/m2 by vein on Day -2.
For participants < 2 years of age: Melphalan 4.7 mg/kg.
Other Name: Alkeran
Mesna by vein on Day -6, after cyclophosphamide to help lower the risk of side effects to the bladder.
Other Name: Mesnex